Small bowel neuroendocrine tumor prognosis

Are you a patient experiencing advanced GIST that is resistant to previous treatments? A wide variety of financial support options for you or your loved ones. Learn more today Survival for stage 4 Around 88 out of 100 people (around 88%) who have a stage 4 tumour, which is grade 1 or grade 2, survive for 1 year or more. Around 71 out of every 100 people (around 71%) who have a stage 4 tumour, which is grade 3, survive for 1 year or more. Read more about grades of small bowel neuroendocrine tumour Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort This study revealed that tumors leading to desmoplastic reaction are more aggressive, despite similar Ki67 indices

Compared with many other GI malignancies, patients with metastatic small bowel NETs have a favorable prognosis: median overall survival was 103 months for patients diagnosed with well-differentiated tumors from 2000 to 2012. 14 During the past decade, results from a number of phase III randomized trials have improved the treatment options for patients with metastatic small bowel NETs Small bowel neuroendocrine tumors (NETs) are increasing in incidence and are now the most common primary malignancies of the small intestine. Despite this increase, the vague presentation and slow growth of these tumors lead to long delays in diagnosis, and many patients present with metastases If you have a neuroendocrine tumour (NET), you may have questions about your prognosis. A prognosis is the doctor's best estimate of how cancer will affect someone and how it will respond to treatment. Prognosis and survival depend on many factors Neuroendocrine tumor signs and symptoms in the duodenum (first part of the small intestine, which connects to the stomach) may include: 19. Abdominal pain. Constipation. Diarrhea. Change in stool color (for example, white or clay colored) Nausea. Vomiting

diagnosis and treatment of small bowel NETs have increased considerably. This review provides a practical framework for the physician who seek to understand the epidemiology, presentation, diagnosis, and management of small bowel NETs. INTRODUCTION Neuroendocrine tumors (NETs) are a di-verse group of neoplasms that arise fro In many cases, neuroendocrine tumors are very small and slow growing. Studies show that these types of tumors can potentially last a lifetime without causing symptoms or spreading. As a result, the survival rate - especially for neuroendocrine tumors that are diagnosed in early stages and properly treated - can be favorable

Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the past decades, and are now the most common type of small bowel tumor. Consequently, general surgeons and surgical oncologists are seeing more patients with SBNETs in their practices than ever before There is no much change in the prognosis of small intestinal neuroendocrine tumors in the last three decades. The survival rate of larger tumors ranges from fifty to seventy percent. Based on several studies it is evident that patients who were diagnosed with liver metastases have poor survival when compared to other carcinoid syndromes

Neuroendocrine Tumor Body of Pancreas with Liver

Introduction. Small bowel neuroendocrine tumours (NETs) are the most common type of gastrointestinal neuroendocrine tumours. The incidence and prevalence of these tumours are on the rise. The aims of this study were to determine prognostic clinicopathological features and whether the ENETS TNM staging system predicts prognosis and also Distant: The cancer has spread to distant parts of the body such as the lungs, liver or bones. 5-year relative survival rates for GI carcinoid tumors (Based on people diagnosed with grade 1 or 2 GI carcinoid tumors [stomach, small intestine, colon, appendix, cecum and rectum] between 2010 and 2016.

Advanced GIST Treatment Option - See The Treatment Overvie

The most common places in the GI tract for this type of tumor are the small intestine and rectum. The 5-year survival rate tells you what percent of people live at least 5 years after the tumor is found. Percent means how many out of 100. In general, the 5-year survival rate for a GI tract NET is 94% Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the lungs, appendix, small intestine, rectum and pancreas. There are many types of neuroendocrine tumors. Some grow slowly and some grow very quickly

Survival for small bowel neuroendocrine tumours Cancer

Bellutti M, Fry LC, Schmitt J, et al.: Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci 54 (5): 1050-8, 2009. [PUBMED Abstract] Almeida N, Figueiredo P, Lopes S, et al.: Double-balloon enteroscopy and small bowel tumors: a South-European single-center experience. Dig Dis Sci 54 (7): 1520-4, 2009 Survival statistics for neuroendocrine tumours (NETs) are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of people, they cannot be used to predict a particular person's chances of survival. There are many different ways to measure and report cancer survival statistics Landerholm et al. reported incomplete tumor resection (HR 2.71, 95% CI: 1.11-6.61) was associated with worse disease-specific survival in patients with small bowel carcinoid tumors. However, our analysis shows no difference in survival between LR and RR (HR 1.01, 95% CI: 0.73-1.40, P=0.92) Enlarge Gastrointestinal carcinoid tumors form in the lining of the gastrointestinal tract, most often in the appendix, small intestine, or rectum.. Gastrointestinal carcinoid tumors form from a certain type of neuroendocrine cell (a type of cell that is like a nerve cell and a hormone-making cell).These cells are scattered throughout the chest and abdomen but most are found in the GI tract

Current studies on the number of removed lymph nodes (LNs) and their prognostic value in small-bowel neuroendocrine tumors (SBNETs) are limited. This study aimed to clarify the prognostic value of removed LNs for SBNETs. SBNET patients without distant metastasis from 2004 to 2017 in the SEER database were included. The optimal cutoff values of examined LNs (ELNs) and negative LNs (NLNs) were. A neuroendocrine tumor (NET) is a rare type of tumor that arises from specialized body cells called neuroendocrine cells.These cells have traits of both nerve cells and hormone-producing cells, and release hormones into the blood in response to signals from the nervous system. Because a neuroendocrine tumor arises from cells that produce hormones, the tumor can also produce hormones Pancreatic neuroendocrine tumors (PNETs) comprise 3-5% of pancreatic malignancies and have a better prognosis than pancreatic exocrine tumors ().Approximately 1,000 are diagnosed per year in the United States ().Significant prognostic factors include tumor grade, tumor size, nodal status, presence of metastatic disease, Ki-67 protein index, and neurovascular invasion

Many GI carcinoid tumors, especially those in the small intestine, make serotonin (also called 5-HT). It is probably the cause of at least some of the symptoms of carcinoid syndrome. The body breaks it down into 5-hydroxyindoleactic acid (5-HIAA), which is released into the urine The treatment options for your neuroendocrine tumor will depend on the type of tumor, its location, and whether you're experiencing signs and symptoms of excess hormones produced by the tumor. In general, neuroendocrine tumor treatment options might include: Surgery. Surgery is used to remove the tumor. When possible, surgeons work to remove.

The Surgical Management of Small Bowel Neuroendocrine Tumors Consensus Guidelines of the North American Neuroendocrine Tumor Society James R. Howe, MD,* Kenneth Cardona, MD,† Douglas L. Fraker, MD,‡ Electron Kebebew, MD, Find Treatment Info for Certain Gastroenteropancreatic Neuroendocrine Tumors

OBJECTIVE: Neuroendocrine tumors (NETs) comprise 41.8% of small intestine malignancies. The NET nomogram is a 15-item prognostic tool that includes relevant factors for guiding management decisions. This is the first external validation of this tool among American patients at a tertiary treatment center Introduction. Primary small bowel neuroendocrine tumors (SBNETs) have unusual patterns of progression compared to most other cancers. The primary tumors remain small and virtually undetectable prior to surgical exploration. 1 Despite the small size of the primary tumor, 60-80% of patients present with liver metastases at diagnosis which are often numerous and bilobar Small intestinal well-differentiated neuroendocrine tumors are the most common primary malignancy of the small intestine [], with an age-adjusted annual incidence of 1.0 per 100,000 for the US. Neuroendocrine tumors (NETs) are a rare, heterogeneous group of tumors, most commonly arising in the gastroenteropancreatic (GEP) tract and lungs [].These tumors show overexpression of somatostatin receptors (SSTRs) on their cell membrane, more frequently type 2 [].In recent years, the incidence and prevalence of NETs have increased, partly because of early detection and longer survival from.

SBNET small bowel neuroendocrine tumor, PNET pancreatic neuroendocrine tumor, CI confidence interval, NA cannot be estimated 0.0 0.2 0.4 0.6 0.8 1.0 02468 Years Proportion 0.0 0.2 0.4 0.6 0.8 1.0 Tumor Type SBNET (n=98) PNET (n=78) Proportion 10 12 14 02468 Years (a) (b)Progression-free Survival by Tumor Type Overall Survival by Tumor Type 10. Well-differentiated small intestine (midgut) neuroendocrine tumors are the second most common primary malignancy in the small intestine, 1 and the small intestine is the most common site for. Introduction. Neuroendocrine tumors (NETs) are rare malignancies of a heterogeneous biologic nature. Their incidence has been increasing over the past decades, and improvements in diagnosis, including imaging as an essential part, are such that these tumors are increasingly diagnosed at a localized stage (), which enables potentially curative resection in many patients The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas 2017; 46:715. Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

This type of tumor is seen in the organs of the gastrointestinal tract as the name suggests. The organs involved are stomach, esophagus, colon, appendix, small intestine, and rectum. Amongst these organs, the neuroendocrine tumors are more commonly seen to begin from the small intestine. These tumors in the small intestine release serotonin Carcinoid tumors are rare tumors that develop from hormone-producing cells called enterochromaffin cells that occur throughout the body, with approximately 65% originating in the gastrointestinal tract and 25% in the lungs.; Carcinoid tumors can occur almost anywhere in the gastrointestinal tract but primarily in the stomach, small intestine, appendix, colon, and rectum

Neuroendocrine tumors (NETs) are heterogeneous neoplasms that originate from cells with a secretory function. Small bowel NETs (SB-NETs) are related to serotonin hypersecretion which causes: flushing, diarrhea, abdominal pain, bronchoconstriction and heart involvement, also known as carcinoid syndrome (CS). CS can be confused with an allergic reaction and thus should be considered as a. tumor mesenteric. Neuroendocrine tumors of the small intestine are rare, but the mesenteric lymph node metastases are present in 80-90% of cases. 8% of desmoid tumors are localized in the mesentery. Other mesentery tumors are rare. Some lesions are classically described in othe For small bowel neuroendocrine tumors (NETs), available evidence and guidelines unanimously recommend resection of a primary tumor site and liver metastatic foci when feasible [31,32,33,34], largely because of the intermittent small bowel obstruction or even ischemia caused by neuroendocrine tumor-associated desmoplastic reaction and fibrosis. Keywords: small bowel neuroendocrine tumor, the log odds of positive lymph nodes, lymph node ratio, survival analysis, prognosis. Citation: Jiang S, Zhao L, Xie C, Su H and Yan Y (2020) Prognostic Performance of Different Lymph Node Staging Systems in Patients With Small Bowel Neuroendocrine Tumors. Front. Endocrinol. 11:402. doi: 10.3389/fendo. Carcinoid syndrome is caused by a neuroendocrine (carcinoid) tumor, and that may lead to liver dysfunction and death in cases where the cancer has spread (metastasized). Still, this is a cancer that responds to treatment and even in advanced stages, the five-year survival rate is almost 70 percent. Early diagnosis leads to a 97 percent survival rate

Tumors of intestineWebpathology

Neuroendocrine tumors of the small intestine causing a

  1. The World Health Organization (WHO) classifies neuroendocrine tumors as well-differentiated neuroendocrine tumors (either the primary tumor or metastasis) and poorly differentiated neuroendocrine carcinomas.5,7,10 Historically, well-differentiated neuroendocrine neoplasms have been referred to as carcinoid tumors, a term which may cause.
  2. al pain or intestinal obstruction. These lesions can create a characteristic fibrotic reaction in the mesentery that may cause kinking of the bowel leading to intermittent.
  3. Neuroendocrine cells are found throughout the body, but mainly in the gastro-intestinal tract (including large bowel and small bowel), pancreas and lungs. Neuroendocrine tumours (also referred to as NET) are an uncommon type of tumour that forms in these cells. The type is generally defined by where the abnormal cells come from and can range.
  4. Small intestine neuroendocrine tumors (NETs) are the second most common malignancy of the gastrointestinal tract. 1 Clinical prognosis is primarily based on stage of disease, with poorer prognosis in patients with metastatic disease compared with those with only local or regional spread. 2-7 However, there remains significant variability in.
  5. Carcinoid tumors are a type of neuroendocrine tumor that can occur along the gastrointestinal (GI) tract. The small intestine is the most common location for GI carcinoid tumors to develop - approximately 40% of all GI carcinoids originate in the small bowel

Management of Small Bowel Neuroendocrine Tumors JCO

  1. Introduction. Patients with small intestine neuroendocrine tumors present with liver metastases in 50-75% of cases at diagnosis. The aim of the present study was to assess prognostic factors in patients with liver metastases from intestinal neuroendocrine tumor after primary tumor surgical removal with or without liver surgery or radiofrequency ablation
  2. A Revolution in the Treatment of Neuroendocrine Tumors. August 9, 2017. Arlene Weintraub. CURE, Rare Cancers - Summer 2017, Volume 1, Issue 1. Patients with neuroendocrine tumors have more treatment options than ever before. RONNY ALLAN, a patient in the United Kingdom who was diagnosed with a metastatic NET in his small intestine in 2010, got.
  3. Poorly differentiated neuroendocrine carcinomas (NECs) originating from the gastrointestinal (GI) tract are rare and very highly malignant disease with a poor prognosis. Poorly differentiated NECs most commonly arise in the esophagus and the large bowel; however, they may occur within virtually any portion of the GI tract. It is known, however, that they do not typically occur in the small.
  4. The incidence of GEP-NETs in Western countries is reported at 5.25 per 100000; the majority of GEP-NETs are located in the small intestine, the remainder either in the rectum or the stomach. *Neoplasia arising from neuroendocrine cells have historically been called carcinoid tumours when occurring in the gastrointestinal tract, however they can.
  5. Epidemiology of Small Intestinal Neuroendocrine Tumors 3 Figure 2. Small intestinal neoplasia incidence, 1973-2002. Over the 30-yr study period, the number and percentage of SI-NETs, adenocar-cinomas, and lymphomas have all increased. Proportionately, NETs have increased to the greatest extent. During the study period, 11,194 cases of small.
Carcinoid tumours of small intestine; surgical aspect

Management of Small Bowel Neuroendocrine Tumor

Symptoms that may or may not include Neuroendocrine Cancer associated syndromes (A syndrome is 2 or more associated symptoms) Small Bowel Neuroendocrine Cancer, in early stage disease, can be a very silent disease - in that symptoms may not be present, however, if symptoms do occur, they may be due to size and position of the cancer - and how it is growing Biliary stone disease (BSD) is common in patients treated with somatostatin analogues (SSA) for Small-intestine neuroendocrine neoplasms (Si-NENs) [1,2,3,4].For this reason, a recent multicentric cohort study suggested the prophylactic cholecystectomy in all patients' candidates to the resection of the primary tumors

Prognosis and survival for neuroendocrine tumours (NETs

Small bowel neuroendocrine tumors (SB-NETs) typically have indolent growth but non-specific symptoms and associated delays in diagnosis often results in advanced stage presentation [1, 2].Distant metastases are present at diagnosis in 30% of patients [1, 2].While metastatic SB-NETs is treatable, it is seldomly curable, such that patients have prolonged survival with persistent disease [1,2,3] Metastatic neuroendocrine cancer prognosis - The neuroendocrine tumor is a rare tumor that presents complex problems for diagnosis and treatment. Even in the case of metastatic spread to the liver, there are some important differences in the nature of these tumors in comparison with gastrointestinal and pancreatic cancer Pathology. Carcinoid tumors are neuroendocrine tumors arising from APUD cells. They can cause a desmoplastic reaction in nearby tissue, leading to fibrosis and tethering of the adjacent bowel 1,3 (for further discussion, see the main article ). The primary tumor in small bowel carcinoid is typically only up to 3.5 cm in size

Learn About Gastrointestinal Neuroendcrine Tumors - NETR

  1. Neuroendocrine Cancer Symptoms. Neuroendocrine systems are mainly concerned with releasing hormones based on neurotic impulses. Hence, the main parts affected by the aggressive varieties of the Neuroendocrine Tumour (NET) include hormonal abnormalities like low blood sugar or heart problems
  2. Small intestinal neuroendocrine tumors were first distinguished from other tumors in 1907. They were named carcinoid tumors because their slow growth was considered to be cancer-like rather than truly cancerous. However, in 1938 it was recognized that some of these small bowel tumors could be malignant
  3. Prognosis. Neuroendocrine lung tumors, also known as pulmonary neuroendocrine carcinomas, are a spectrum of cancers that arise in neuroendocrine cells of the lungs. The majority are classified as small cell lung carcinomas (SCLCs), aggressive cancers that can affect neuroendocrine and other cell types. Others are carcinoid tumors, a rare and.
  4. Introduction. Small bowel tumours are rare, accounting for <5% of all gastrointestinal cancers (despite the small intestine contains over 90% of the mucosal surface area of the GI tract), and in the UK, their incidence is around 2-3 cases per 100,000 per year.. Most small bowel tumours arise from the duodenum (around 55-82% of cases), and less commonly arise from the jejunum (11-25%) or ileum.

  1. Malignant tumors include adenocarcinomas, neuroendocrine tumors (carcinoids), stromal tumors, and lymphomas. Benign lesions that may arise in the small bowel include adenomas, leiomyomas, fibromas, and lipomas. The diagnosis and staging of small bowel tumors will be reviewed here
  2. Carcinoid of the small intestine, a well-differentiated neuroendocrine tumor, is the most common distal small bowel malignancy, with an occurrence rate of one case per 300 autopsies. Carcinoid tumors of the appendix account for 0
  3. Neuroendocrine tumours are sometimes referred to as carcinoid tumours, particularly when they affect the small bowel, large bowel or appendix. Carcinoid syndrome is the collection of symptoms some people with a neuroendocrine tumour may have

Neuroendocrine Tumor Survival Rate Moffit

Neuroendocrine tumor. . The small bowel and especially the terminal ileum is the most common location of this type of gastrointestinal tumors. In this case, endoluminal growth is more common and calcifications can be present in 70% of the patients, more frequently than GIST. It can be quite similar to GIST in imaging, appearing as an. Purpose: Small intestinal neuroendocrine tumors (SINET) are the commonest malignancy of the small intestine; however, underlying pathogenic mechanisms remain poorly characterized. Whole-genome and -exome sequencing has demonstrated that SINETs are mutationally quiet, with the most frequent known mutation in the cyclin-dependent kinase inhibitor 1B gene ( CDKN1B ) occurring in only ∼8% of. Cancer of the small intestine, carcinoid; Carcinoma neuroendocrine small intestine; Malignant carcinoid tumor of small intestine; Primary malignant neuroendocrine tumor of small intestine; ICD-10-CM C7A.019 is grouped within Diagnostic Related Group(s) (MS-DRG v 38.0): 374 Digestive malignancy with mcc; 375 Digestive malignancy with c Somatostatinomas are rare tumours. They are usually in the pancreas or parts of the small bowel (the duodenum or jejunum). They make extra somatostatin. This is a hormone that stops the pancreas producing other hormones. Somatostatin also affects how the digestive system works. Common symptoms of a somatostatinoma include Pancreatic neuroendocrine tumours (PanNETs, PETs, or PNETs), often referred to as islet cell tumours, or pancreatic endocrine tumours are neuroendocrine neoplasms that arise from cells of the endocrine and nervous system within the pancreas.. PanNETs are a type of neuroendocrine tumor, representing about one third of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

The Surgical Management of Small Bowel Neuroendocrine Tumor

Background: The 8th edition AJCC Staging for small bowel neuroendocrine tumors created a novel N2 classification. This study investigates if it is independently prognostic. Methods: Records of patients from 2008 to 2019 were reviewed. Survival rates were estimated by Kaplan-Meier method and compared by log-rank The combination of a lengthy road-bike ride, a recovery drink mix, and dried figs from Trader Joe's led to a health crisis for Steven Muller and a subsequent diagnosis of a neuroendocrine tumor (NET) in his small intestine. Neuroendocrine tumors, including carcinoid cancer, pancreatic neuroendocrine tumors, pheochromocytoma and multiple. Background The diagnosis of small‐bowel neuroendocrine tumors (SbNETs) has improved with the advent of video capsule endoscopy (CE) and double‐balloon enteroscopy (DBE). The data describing the eff..

Neuroendocrine cells are found throughout the body, in organs such as the stomach, bowel and lungs. NETs can be non-cancerous (benign) or cancerous (malignant). This information is about malignant tumours. It is mainly about NETs that affect the digestive system small bowel NETs, prognosis. Introduction: Most gastrointestinal neuroendocrine tumors (GI-NETs) involve the small intestine (38%) and about 50% of patients present with regional or distant metastases at time of diagnosis [2]. 68Ga-DOTATATE PET/CT provides improved sensitivity and specificity compared to traditional nuclear medicine techniques [4]. ]. However, there is relatively less data. Neuroendocrine tumors (NETs), defined as epithelial tumors with predominant neuroendocrine differenti-ation, are among the most frequent types of small bowel neoplasm. They represent a rare, slow-growing neoplasm with some characteristics common to all forms and others attributable to the organ of origin. Th

What Is The Prognosis For Neuroendocrine Tumors

Abstract. Neuroendocrine tumors (NETs), defined as epithelial tumors with predominant neuroendocrine differentiation, are among the most frequent types of small bowel neoplasm. They represent a rare, slow-growing neoplasm with some characteristics common to all forms and others attributable to the organ of origin Conclusions and Relevance The findings from this study suggest that, for patients undergoing curative-intent resection of small-bowel neuroendocrine tumors, accurate lymph node staging requires a minimum of 8 lymph nodes for examination, and 4 or more positive lymph nodes are associated with decreased 3-year recurrence-free survival compared. Clinical features by site. Ampullary well differentiated neuroendocrine tumor: 3% of ampullary tumors. Patients typically present with jaundice. Compared to duodenal carcinoids (which are usually benign), are more aggressive with shorter survival (may die within 1 year), have more metastases. Somatostatin producing tumors are common, have a. Symptoms of neuroendocrine carcinoma can include: Hyperglycemia (too much sugar in the blood) Hypoglycemia (too little sugar in the blood) Diarrhea. Persistent pain in a specific area. Loss of appetite/weight loss. Persistent cough or hoarseness. Thickening or lump in any part of the body. Changes in bowel or bladder habits

1cm Neuroendocrine Tumor Body of Pancreas - Pancreas Case

Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45:1483-6. 17. Qian ZR, Ter-Minassian M, Chan JA, et al. Prognostic significance of mTOR pathway component expression in neuroendocrine tumors. J Clin Oncol. 2013;31:3418-25. 18 Carcinoid tumors are relatively rare neuroendocrine tumors. They constitute approximately 2% of all gastrointestinal tumors [].However, carcinoid tumors are the second most common small-bowel malignancy [].Carcinoid tumors belong to a category of tumors called apudomas (amine precursor uptake and decarboxylation tumors) because they arise from endocrine amine precursor uptake and. Introduction . Small bowel cancers are rare. Accumulation of data regarding their clinical presentation, pathologic features, prognostic factors, treatment modalities, and outcome is difficult. Methods . This is a retrospective study of the medical records of 33 patients with small bowel cancers treated at the American University of Beirut-Medical Center over a 20-year period. <i>Results</i> Hi Pickle71 and a very warm welcome to the online community. I had a different type of cancer to you but it's always good to be able to share experiences with others who have the same type. I noticed that you hadn't had any replies to your post so I used the group's search facility to see if anyone else here has mentioned having a neuroendocrine tumour in their small bowel but drew a blank I'm.

Endocrine tumors of gitSI and LI --&gt; Cancer flashcards | Quizlet

Carcinoid tumors are the most common type of neuroendocrine tumor. An estimated 11,000 to 12,000 people are diagnosed with a carcinoid tumor each year in the United States. About two-thirds of all carcinoid tumors appear in the gastrointestinal system, particularly in the small intestine, rectum, stomach, colon, and liver has also been recognized. The small intestine appears to be the most frequent site, replacing the appendix [10-12]. In addition, SiNETs are the most common small bowel neoplasms, and they account for approximately one third of all neuroendocrine tumors [9, 14-17]. There has also been an increasing percentage of tumors diagnosed at a Basically, neuroendocrine tumors are cancers that can develop anywhere endocrine cells are present. Endocrine cells help regulate various body functions, such as growth, reproduction and metabolism. They are distributed throughout the body, but the most common places for tumors to develop from them are in the lungs, small intestines and pancreas